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Superior vena cava (SVC) syndrome has a characteristicand often striking clinical presentation, which can occa-
sionally be life threatening. It is caused by obstruction of the
SVC either by extrinsic compression or internal thrombus.
Clinical signs include cyanosis, plethora, distention of sub-
cutaneous vessels, and edema of the arms, head and neck.
Edema may compromise the function of the larynx or phar-
ynx, causing dyspnea, stridor, cough, hoarseness, and dys-
phagia. A more serious sequela is cerebral edema, causing
headaches, confusion, and possibly coma. Cardiac output
may be diminished transiently by acute SVC obstruction.
However, within a few hours, the increased venous pressure
forces blood through collaterals so that a steady state of blood
return is once again achieved. Evidence of hemodynamic
compromise is usually a result of mass effect on the heart
itself rather than the SVC compression.1–5
Traditionally, SVC syndrome has been viewed as a
relative emergency. However, a recent review of data6 reveals
that in most instances the course is relatively benign, and in
fact often improves without any active treatment.5 Which
patients require urgent intervention and which patients re-
quire little specific treatment for SVC syndrome has not been
well defined. There are no detailed guidelines addressing the
management of SVC obstruction. Though a general recom-
mendation supporting the consideration of radiotherapy
and/or stent placement for symptomatic SVC obstruction
from lung cancer has been made both by the American
College of Chest Physicians and the National Comprehensive
Cancer Network, specific recommendations are currently
lacking. Definition of the management is particularly impor-
tant as the spectrum of possible interventions has increased,
from radiotherapy and chemotherapy to thrombolytics and
SVC stenting.
Definition of a nuanced approach to patients with SVC
syndrome has been hampered by lack of a method to describe
variations in the presentation of such patients. The purpose of
this article is to propose a classification scheme for patients
with SVC obstruction according to the severity of symptoms.
This in turn provides a basis for a treatment algorithm,
matching different interventions with the severity of symp-
toms to define a rational framework of how to approach these
patients.
SYMPTOMS AND PHYSIOLOGY OF SVC
OBSTRUCTION
If the SVC becomes obstructed, blood flows through
multiple smaller collaterals to the azygous vein or the inferior
vena cava. These venous collaterals dilate over several
weeks, so that the upper body venous pressure is markedly
elevated initially but decreases over time.7,8 The severity of
symptoms depends on how quickly the SVC obstruction has
developed and the degree of narrowing, although acute
thrombosis can also occur causing sudden exacerbation of a
partial obstruction. Furthermore, the effect of SVC obstruc-
tion may be difficult to separate from the impact of compres-
sion of the heart, lungs, or airways from a large intrathoracic
mass.
Elevated venous pressure causes interstitial edema of
the head and neck that is visually often striking, but generally
of little consequence. However, edema may narrow the lumen
of the nasal passages and larynx, which can be life-threaten-
ing if severe, especially because intubation may be difficult to
perform. Cerebral edema can also occur and can lead to
cerebral ischemia, herniation, and death because the skull
creates a closed compartment. Elevation of the head is usu-
ally of little benefit if venous collaterals have not yet dilated
enough and hyperventilation may be problematic because of
difficulties with intubation. Cardiac output may be dimin-
ished transiently by acute SVC obstruction, but within a few
hours a steady state of blood return is achieved by the
increased venous pressure and collaterals. Hemodynamic
compromise is usually a result of mass effect on the heart
rather than the SVC compression.6
Signs and symptoms of SVC obstruction however, are
usually more of a nuisance than of clinical consequence. In a
review of 1986 cases of SVC obstruction, only one docu-
mented case of death was found, in this case from epistaxis.9
Two additional deaths resulted from rupture of an aortic
aneurysm that was causing SVC syndrome. Only anecdotal
cases of neurologic or laryngeal compromise were identified,
and in these it was unclear whether the symptoms were
caused by other factors (brain metastases or tracheal com-
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pression).9,10 Furthermore, in animal studies acute ligation of
the SVC above the azygous vein resulted in listless behavior
that resolved with 1 week in all cases.11
CLINICAL EVALUATION
Patient evaluation should begin with a history and
physical examination with attention to the duration of symp-
toms, a history of previous invasive procedures, and a history
of malignancy. The diagnosis of SVC syndrome is made
clinically on the basis of signs and symptoms, as listed in
Table 1. In most cases symptoms are generally progressive
over several weeks and then get better over time.6 Further
investigation must be performed to look for related additional
problems as these are common in patients with malignant
SVC syndrome. These can include the presence of brain
metastases, major compression of the tracheobronchial tree,
or of the heart from mass effect. These additional issues may
cause symptoms by themselves that may be mistakenly at-
tributed to SVC obstruction if a thoughtful and careful history
and examination is not done.
PROPOSED CLASSIFICATION SYSTEM
The severity of symptoms is important in determining
the urgency of intervention. This has not been well charac-
terized in existing studies because of the lack of a classifica-
tion scheme. A proposed scheme is shown in Table 2. Use of
this schema in future studies should provide a common
language to describe the patients and thereby help define the
role of interventions. This schema is patterned after the
Common Terminology Criteria for Adverse Events (CTCAE)
v3.0 of the National Institutes of Health and divided into
mild, moderate, severe, life threatening, and fatal symptoms.
However, it should be emphasized that grade 3, 4, or 5
symptoms are quite rare. The CTCAE does not address SVC
syndrome, although it does include a category of edema of
the head and neck. The grading in this CTCAE category is
similar to the proposed schema, except that the CTCAE is
more narrowly focused whereas the proposed schema in-
cludes all symptoms caused by SVC obstruction.
Because the severity of symptoms of SVC syndrome
change over time, the time point at which the symptoms are
graded must be included in future studies using the proposed
classification system. For example, important time points
might be at the time of presentation, at the time of initiation
of treatment, or after the treatment has been finished. Assess-
ment of the efficacy of a treatment could be measured by a
change in symptom severity from just before treatment to
after completion of treatment. Ideally one would have a
comparison group who did not get the treatment, otherwise it
is difficult to evaluate the effect of the treatment versus the
simple passage of time.
An important feature of the proposed grading system is
the differentiation between severe, life-threatening, and non-
life threatening situations. Severe symptoms are classified as
including mild or moderate cerebral edema causing headache
and dizziness, mild or moderate laryngeal edema, or di-
minished cardiac reserve manifesting as syncope after
bending. Life threatening symptoms include significant
cerebral edema causing confusion and obtundation, signif-
icant laryngeal edema causing stridor and potential airway
compromise, significant hemodynamic compromise caus-
ing syncope without precipitating factors, hypotension, or
renal insufficiency.
TREATMENT ALGORITHM FOR MALIGNANT
CAUSES
In the case of a malignancy causing SVC obstruction,
management issues include treatment of the malignancy itself
and treatment aimed at relief of the symptoms of SVC
obstruction. A median life expectancy of about 6 months
has been noted in patients with malignant SVC obstruc-
tion.4,5,12,13 However, there are numerous reports of patients
achieving long-term (5 years) survival after treatment of
malignant SVC obstruction,12 and the survival of patients
presenting with SVC obstruction does not seem to be differ-
ent from that of patients with the same tumor type and stage
without SVC obstruction.3,9,14,15 Thus, it appears clear that
the presence of malignant SVC obstruction does not alter the
need to treat the underlying malignancy as dictated by the
type and stage of tumor.
Management of the SVC obstruction itself is dictated
by the severity of the symptoms, the likelihood of response to
a particular treatment, and the treatment of the malignancy
itself. Thus, the right approach will be influenced by the
symptoms, the type and stage of malignancy, the patient’s
performance status, and comorbidities. Traditional medical
treatment such as corticosteroids and diuretics are not sup-
ported by data demonstrating benefit.6
When symptoms are life threatening (grade 4), imme-
diate intervention is indicated and should be directed at
TABLE 1. Symptoms and Signs Associated with Superior
Vena Cava Syndrome
Sign or Symptom
Percentage of
All Patients
Reported
Range (%)
Hemodynamic
Facial edema 82 60–100
Arm edema 46 14–75
Distended neck veins 63 27–86
Distended chest veins 53 38–67
Facial plethora 20 13–23
Visual symptoms 2 —
Respiratory
Dyspnea 54 23–74
Cough 54 38–70
Hoarseness 17 —
Stridor 4 —
Neurologic
Syncope 10 8–13
Headaches 9 6–11
Dizziness 6 2–10
Confusion 4 —
Obtundation/CVA 2 —
Data from Refs. 1, 4, 5, 21, 22, 23.
CVA, cerebral vascular accident (stroke).
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urgent relief of the SVC obstruction (Figure 1). Intravascular
stenting is safe and provides the most immediate relief.6 An
intervention to relieve the obstruction can be done before
obtaining a tissue diagnosis.6 Stenting can often be accom-
plished even if there is complete SVC obstruction or throm-
bosis, particularly is thrombolytics are first used.6
An argument can be made to extend the recommenda-
tion for stenting to patients with grade 3 symptoms; however,
this is probably best reserved for those patients unable to
tolerate optimal treatment of their underlying malignancy or
patients with persistent symptoms after treatment. This rec-
ommendation is based on the need for treatment of the
underlying malignancy, the generally good response rates
(even with time alone), and the cost of stenting.
If symptoms are not life threatening, the ultimate
outcome and survival from SVC syndrome is dependent on
the underlying root cause. Therefore, patients with grade 1
and 2 and most with grade 3 symptoms should undergo
diagnostic and staging procedures to define the tumor type
and stage. The data clearly shows that this can be accom-
plished safely in experienced hands despite SVC obstruc-
tion.6 A stage- and tumor-specific treatment plan should be
FIGURE 1. Proposed management algorithm.
TABLE 2. Proposed Grading System for Superior Vena Cava Syndrome
Grade Category
Estimated
Incidence (%) Definitiona
0 Asymptomatic 10 Radiographic superior vena cava obstruction in the absence of symptoms
1 Mild 25 Edema in head or neck (vascular distention), cyanosis, plethora
2 Moderate 50 Edema in head or neck with functional impairment (mild dysphagia, cough,
mild or moderate impairment of head, jaw or eyelid movements, visual
disturbances caused by ocular edema)
3 Severe 10 Mild or moderate cerebral edema (headache, dizziness) or mild/moderate
laryngeal edema or diminished cardiac reserve (syncope after bending)
4 Life-threatening 5 Significant cerebral edema (confusion, obtundation) or significant laryngeal
edema (stridor) or significant hemodynamic compromise (syncope without
precipitating factors, hypotension, renal insufficiency)
5 Fatal 1 Death
a Each sign or symptom must be thought due to superior vena cava obstruction and the effects of cerebral or laryngeal edema or effects on cardiac function.
Symptoms caused by other factors (e.g., vocal cord paralysis, compromise of the tracheobronchial tree, or heart as a result of mass effect) should be not be
considered as they are due to mass effect on other organs and not superior vena cava obstruction.
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developed (typically the same treatment as for patients
without caval obstruction).
Patients with lymphoma, small-cell lung cancer, and
germ cell tumors should experience a rapid clinical response
from systemic chemotherapy. Stenting is of questionable
value in such patients. The majority of patients with non–
small-cell lung cancer experience relief of obstructive symp-
toms with definitive treatment (chemotherapy for stage IV,
chemoradiotherapy for stage III), but the rate of response is
less than that seen in more chemo and radiosensitive tumors.6
Stent placement in such patients with grade 3 symptoms may
be reasonable. Stenting should be strongly considered in
patients with tumors for which effective treatment approaches
are very limited (e.g., mesothelioma). Patients with thymoma
and caval obstruction should undergo chemotherapy followed
by resection,16 and stenting should be avoided because it
complicates resection.
The benefit of anticoagulation is unclear, although
thrombolytics are useful if there is caval thrombosis.12,17,18
Anticoagulation after thrombolysis and consideration of the
use of aspirin after stent placement alone has been recom-
mended by several authors.12,17
Whether a brain metastasis should affect the manage-
ment of SVC syndrome is unclear. Stenting for such patients
has been considered because of the potential of increased
cerebral edema, but at least temporary anticoagulation is
needed and cerebral hemorrhage has been documented. For
those with both SVC syndrome and airway obstruction,
optimal management approaches are uncertain. Some suggest
resection (either complete or subtotal) to establish immediate
and simultaneous relief of the clinical problems.19,20 The treat-
ment of relapsed SVC obstruction is unclear. Stenting should be
considered because the response to additional chemotherapy or
radiation may be limited or technically not possible.
CONCLUSION
In conclusion, we have proposed a grading system
based on clinical findings for SVC syndrome from malignant
causes. We hope this grading system will facilitate commu-
nication and allow collation and comparison of results from
different institutions. We have proposed an algorithm for the
treatment of SVC syndrome based the presence or absence of
potential life-threatening symptoms, performance status of
the patient, and the histology of the tumor (Figure 1). Both
the grading system and the management algorithm need
validation and further refinement. However, we hope they
provide a starting point that allows an evidence-based ap-
proach to develop.
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